Core--Cellular therapy

核心--细胞治疗

• 批准号: 6728867
• 负责人: Shelly Heimfeld
• 金额: $ 7.78万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-03-12 至 2007-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6728867
• 关键词: animal tissue; biomedical facility; blood treatment; cell population study; cell transplantation; flow cytometry; human tissue; tissue /cell culture; transplantation immunology

The Cellular Therapy Shared Resource is an integral part of the Consortium and plays a critical role in the Clinical Transplantation program. Cellular Therapy helps support research by providing four specific functions. First, the resource provides the critical instrumentation and technical expertise in apheresis collection, cell processing, cryopreservation, and the infusion of cells. Included within this objective are the development of new cell selection and culturing techniques in support of novel autologous and allogeneic treatment protocols. Second, Cellular Therapy provides large-scale processing capabilities in support of specific research studies involving human, primate, and canine cells. This again encompasses the development of novel cell selection approaches and the preclinical validation of such research procedures for implementation in clinical studies. Third, the laboratory performs quantitative flow cytometry analyses and in vitro colony forming assays on various cellular components utilized for both clinical and research studies. These data are useful in determining which specific cell populations may be correlated with specific clinical outcomes. This in turn helps to stimulate the development of novel graft engineering approaches and techniques that could improve future transplantation studies. Fourth, Cellular Therapy procures and provides both patient and normal donor specimens in support of research projects. These samples, obtained under IRB approved protocols from fresh specimens and from an already established Repository Specimens for Research Studies, will be extremely useful in helping Center investigators to define the mechanisms involved in engraftment, disease control, immune reconstitution, and graft-versus-host disease. This application requests continued support for a resource which fulfills an essential role for peer reviewed research.

细胞疗法共享资源是财团不可或缺的一部分，在临床移植计划中起着至关重要的作用。细胞疗法通过提供四个特定功能来帮助支持研究。首先，该资源提供了仪器和技术专长，以收集（细胞加工，冷冻保存以及细胞输注）。该目标包括开发新的细胞选择和培养技术，以支持新型的自体和同种异体治疗方案。其次，细胞疗法提供了大规模的加工能力，以支持涉及人类，灵长类动物和犬类细胞的特定研究。这再次涵盖了新型细胞选择方法的发展以及对临床研究实施的此类研究程序的临床前验证。第三，实验室对用于临床和研究的各种细胞成分进行定量流式细胞仪分析和体外菌落形成测定。这些数据可用于确定哪些特定细胞群可能与特定的临床结果相关。反过来，这有助于刺激新型移植工程方法和技术的发展，从而可以改善未来的移植研究。第四，细胞疗法采购，并为支持研究项目提供患者和正常供体标本。这些样本，在 IRB批准了来自新样本的协议以及已经建立的存储库 研究研究的标本将在帮助中心研究人员定义植入，疾病控制，免疫结构和移植物与宿主病的机制方面非常有用。该应用程序要求继续支持一种资源，该资源履行了同行评审研究的重要作用。